Publications by authors named "Ruddy K"
Background: Glomerular filtration rate (GFR) assessment is important in clinical practice, with implications for diagnosis, prognostication, and drug dosing. People with cancer are at risk of imprecision in GFR estimation. This cross-sectional study evaluated the performance of various creatinine and cystatin C-based equations in comparison to measured GFR (mGFR) in people with cancer.
View Article and Find Full Text PDFPurpose: Over 50% of households in the United States have at least one musician-many musicians are also breast cancer survivors. This group has not been well studied, and given the level of fine sensory-motor skill required for musicianship, we hypothesized that musicians experience unique manifestations of breast cancer treatment toxicities.
Methods: A nine-item Musical Toxicity Questionnaire (MTQ) was distributed to patients who had consented to participate in the Mayo Clinic Breast Cancer Registry.
Chemotherapy-induced peripheral neuropathy (CIPN) from oxaliplatin and taxane drugs is a bothersome toxicity. Palmitoylethanolamide (PEA) has been reported to improve myelinated nerve fiber function in patients experiencing painful CIPN. We conducted a double-blind, placebo-controlled, randomized trial of PEA in patients with established CIPN.
View Article and Find Full Text PDFArticle Synopsis
- - Breast cancer survivors face a heightened risk of cardiovascular disease (CVD) mainly due to the cardiotoxic effects of some cancer treatments and shared risk factors.
- - A PubMed review analyzed 152 studies to gather insights on cardiovascular health management for these survivors, highlighting common risk factors like obesity, inactivity, and smoking.
- - Primary care physicians play a crucial role in the long-term care of breast cancer survivors, needing to monitor CVD risks, perform evaluations, and refer to specialists as necessary.
Background: Retrospective studies suggest that some breast cancer survivors report treatment-associated hair loss or thinning years after their diagnosis. This study investigates frequency and perceptions of alopecia persisting 6 years after patients' breast cancer diagnoses.
Methods: Breast cancer survivors participating in the Mayo Clinic Breast Disease Registry (MCBDR) were mailed a survey 6 years after diagnosis.
Importance: Young adults aged 18 to 39 years represent the minority of breast cancer diagnoses but are particularly vulnerable to financial hardship. Factors contributing to sustained financial hardship are unknown.
Objectives: To identify financial hardship patterns over time and characterize factors associated with discrete trajectories; it was hypothesized that treatment-related arm morbidity, a key source of expense, would be associated with long-term financial difficulty.
Purpose: This study evaluates real-world outcomes, toxicities, and prescribing patterns of PARP inhibitors (PARPis) for the treatment of metastatic breast cancer (MBC).
Patients And Methods: Electronic health records of 62 MBC patients treated with olaparib (n = 48) or talazoparib (n = 14) at Mayo Clinic System between 2017 and 2022 were analyzed. Time-to-treatment-failure (TTF) was assessed utilizing the Kaplan-Meier method.
Purpose: To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS).
Experimental Design: Germline PV frequencies in breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, RAD51C, and RAD51D) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort (n = 9,887), a population-based cohort (n = 3,876), and the UK Biobank (n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort.
Article Synopsis
- HR-negative, HER2-positive breast cancer can have favorable outcomes if treated with HER2-targeted therapy, and Medicaid expansion under the ACA may improve care access and effectiveness for this group.
- A study analyzed the impact of Medicaid expansion on treatment adherence, timely initiation of therapy, and survival rates in women aged 18 to 62 diagnosed with this type of breast cancer between 2010 and 2018.
- Results showed that Medicaid expansion led to a slight increase in receiving guideline-concordant treatment and significantly improved timely treatment initiation and 2-year survival rates, especially for those with advanced stage III disease.
Article Synopsis
- Pathogenic variants (PVs) in certain genes like BRCA1 and BRCA2 increase breast cancer risk, but it's unclear how risk varies based on the type and location of these variants.
- This study analyzed breast cancer risks associated with different PV types and locations using data from 12 US studies and clinical cohorts involving over 64,000 women.
- Results showed that women with specific exon PTVs had higher breast cancer risks, lower rates of ER-negative breast cancer, and were diagnosed at younger ages compared to those with other variants, with these patterns observed across multiple cohorts.
Background: Eyebrow and eyelash loss, known as madarosis, can occur after breast cancer-directed therapy. The purpose of this study was to ascertain the proportion of breast cancer survivors who experience madarosis, contributing factors, and associations between this symptom and quality of life.
Methods: Breast cancer survivors were invited to participate in an ongoing longitudinal cohort study as a part of the Mayo Clinic Breast Disease Registry (MCBDR).
Article Synopsis
- Many young women diagnosed with breast cancer (BC) are interested in breastfeeding after treatment, but there's limited information on their experiences.
- In a study of 143 women diagnosed with BC, around 55% attempted breastfeeding, with satisfaction rates high despite challenges such as mastectomies and low milk production.
- There's a need for more specific resources and support for BC survivors who want to breastfeed, as many women reported receiving helpful information only from their oncology teams or online.*
Objective: To evaluate contraception use and change among young women with early breast cancer.
Design: Secondary analysis of a cluster randomized trial.
Setting: Multi-institutional.
Purpose: The optimal approach for partial breast irradiation (PBI) is unknown. We investigated a novel de-intensified 3-fraction PBI regimen for photons, protons, and brachytherapy.
Methods And Materials: A multicenter nonrandomized controlled trial with the primary outcome of adverse cosmesis at 3 years versus before PBI.
Article Synopsis
- Young women with breast cancer have a higher likelihood of carrying harmful BRCA gene variants, but data on tumor histology's prognostic value is limited.
- A study involving 4,628 patients revealed that lobular tumors are generally diagnosed at a later stage and are more often linked to BRCA2 mutations, while ductal tumors are frequently associated with BRCA1 mutations.
- Despite differences in tumor characteristics and treatment approaches, the study found no significant differences in disease-free or overall survival between those with ductal and lobular tumors, indicating that histology may not influence prognosis.
Article Synopsis
- Clinical genetic testing helps find cancer risks by identifying gene changes, but some of these changes are confusing because we don't know what they mean (called VUS).
- Researchers studied a huge number of breast cancer patients and healthy people to understand these confusing gene changes better.
- They found that their method of analyzing data closely matches what other experts say about which gene changes are harmless or harmful, giving more information about 785 unclear changes.
Article Synopsis
- * It analyzed over 1000 participants from ages 14 to 23 to determine if issues with sustained attention predict future substance use rather than being just a side effect.
- * The results showed that strong brain connections related to sustained attention at age 14 can predict an increase in cannabis and cigarette use later, highlighting sustained attention as a key indicator of vulnerability to substance use.
Objectives: We describe the development and implementation of a system for monitoring patient-reported adverse events and quality of life using electronic Patient Reported Outcome (ePRO) instruments in the I-SPY2 Trial, a phase II clinical trial for locally advanced breast cancer. We describe the administration of technological, workflow, and behavior change interventions and their associated impact on questionnaire completion.
Materials And Methods: Using the OpenClinica electronic data capture system, we developed rules-based logic to build automated ePRO surveys, customized to the I-SPY2 treatment schedule.
Article Synopsis
- The Advocate-BREAST project aims to enhance the breast cancer patient experience through targeted education and patient-centered research.* -
- A survey sent to nearly 7,000 breast cancer survivors revealed high satisfaction with care but identified significant concerns regarding symptoms and support, particularly around issues like sexual dysfunction and emotional health.* -
- Patients expressed a need for better psychological support and clear educational resources, leading to proposed Quality Improvement projects focusing on holistic care and wellness programs.*
Purpose: The enhanced, electronic health record (EHR)-facilitated cancer symptom control (E2C2) trial is a cohort cluster-randomized, stepped-wedge, hybrid type II trial that leverages EHR systems to facilitate a collaborative care model (CCM) approach with the goal of improving cancer symptom management. Understanding factors that influence care team adoption of EHR systems remains a critical understudied area of research. This study examines how oncology care teams' perceptions regarding the feasibility, acceptability, and appropriateness of E2C2 EHR systems preimplementation were associated with adoption 3 months after implementation and characterizes differences in adoption by individual- and system-level factors.
View Article and Find Full Text PDFArticle Synopsis
- Young women with a type of breast cancer called HR-positive can benefit from a treatment that suppresses ovarian function, but they might still have some hormones called estrogen (E2) that sneak through.
- In a study of women under 40, many still had higher levels of estrogen 1 and 4 years after starting treatment, especially if they hadn't had chemotherapy before.
- The study found that the estrogen levels didn't really change the chances of surviving early cancer, but for more advanced cases, those with higher estrogen levels seemed to have a higher death rate, suggesting we need more research to find the best treatment.
Article Synopsis
- - The study, Advocate-BREAST80+, assessed the needs of breast cancer patients aged 80 and older (P80+) compared to younger patients (P80-).
- - A survey was conducted with 6,918 participants from the Mayo Clinic Breast Disease Registry, finding that P80+ were less likely to receive certain therapies and were significantly less satisfied with information about side effects and management.
- - While P80+ reported lower anxiety levels, they were much less involved in clinical trials and showed little interest in participating in future studies, highlighting a need for improved education and support for this age group.
Article Synopsis
- - This study investigates the molecular differences between breast cancer survivors and healthy controls using advanced techniques like genomics and metabolomics, involving a total of 100 participants.
- - Findings revealed that breast cancer survivors had higher polygenic risk scores and notable differences in metabolites, particularly lower Omega-3 Index levels, compared to healthy individuals.
- - The research contributes significant data that can help identify patterns in breast cancer survivorship, with the potential to inform new treatment strategies and improve the quality of life for those affected.
Article Synopsis
- - The study examined the cardiovascular disease (CVD) risk linked to cancer treatments in young women (≤40 years) with breast cancer, focusing on data from 372 survivors over five years.
- - Findings revealed that radiation treatment, especially left-sided radiation, was associated with a significant increase in excess heart age, while systemic cancer treatments showed no correlation with heart age changes.
- - The authors suggest that CVD risk assessment tools should integrate cancer treatment history to better identify young breast cancer survivors at high risk for cardiovascular issues.
Purpose: Compared with older women diagnosed with breast cancer, younger women are more likely to die of breast cancer and more likely to suffer psychosocially in both the short-term and long term. The Young Women's Breast Cancer Study (YWS) is a multisite prospective cohort study established to address gaps in our knowledge about this vulnerable and understudied population.
Participants: The YWS enrolled 1302 women newly diagnosed with stages 0-IV breast cancer at age 40 years or younger at 13 academic and community sites in North America between 2006 and 2016.